Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqi Simiao Decoction (HSD) is a traditional Chinese medicine (TCM) herbal formula used primarily for the treatment of type 2 diabetes mellitus and related metabolic disorders. The decoction consists of multiple herbs, with key active components identified as quercetin, kaempferol, stigmasterol, baicalein, β-sitosterol, flavodoxin, canthaxanthin, and berberine. Mechanistic studies using network pharmacology and metabolomics suggest that HSD exerts its effects by modulating several biological targets including AKT1, TP53, TNF (tumor necrosis factor), IL6 (interleukin-6), and VEGFA (vascular endothelial growth factor A). These actions influence metabolic pathways such as amino acid metabolism and the tricarboxylic acid cycle. The decoction is believed to improve glucose metabolism and reduce inflammation through multi-target interactions[1][2]. It is typically prescribed in TCM practice for patients with type 2 diabetes presenting with "damp-heat" syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangqi Simiao Decoction.